NAD+ is the longevity industry's favourite molecule, and the science underneath it is real. The gap between that science and the $186-a-month injection being sold to you at GLP-1 checkout is where this article lives.
Nicotinamide adenine dinucleotide — NAD — is a coenzyme found in every cell in your body. It is genuinely central to metabolism: its main job is helping convert food into usable energy, and it participates in DNA repair and cellular signalling. NAD levels do decline with age. None of that is marketing; it is textbook biochemistry.
The marketing begins one step later, at the inference that topping NAD back up will reverse the consequences of it having fallen. That step has not been demonstrated in humans, and the distance between "this molecule matters" and "buying this molecule helps you" is where an entire industry has been built.
What NAD+ does, accurately
NAD acts as an electron carrier in the reactions that extract energy from food. It is also consumed by enzymes involved in DNA repair and in regulating cellular stress responses — sirtuins and PARPs, if you want the names. Because those enzymes use NAD up, sustained cellular stress depletes it.
Levels do fall with age, and researchers have reasonably asked whether that decline contributes to age-related dysfunction or merely accompanies it. That is an open and legitimate research question. It is not a settled finding, and the direction of causation matters enormously for whether supplementation should help.
“There's currently not enough research to confirm the energy and anti-aging benefits attributed to NAD+ supplements.”
— Cleveland Clinic, reviewing the evidence on NAD+ supplementation, February 2026
Injection, IV, nasal spray or pill — does the route matter?
Clinics make a lot of the delivery route, and there is a kernel of truth in it: NAD is a large, unstable molecule, and oral bioavailability is genuinely poor. That is why most oral products contain precursors — nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) — rather than NAD itself, on the theory that your body will convert them.
Where the argument overreaches is in treating better delivery as equivalent to demonstrated benefit. Getting more of a substance into the bloodstream only matters if the substance does what is claimed once it arrives. Higher blood levels are a surrogate, not an outcome, and the human trials that would connect the two are largely missing.
How NAD+ products are typically sold, and what each route actually establishes
| Route | Typical price | Absorption argument | What is demonstrated |
|---|---|---|---|
| IV infusion | $200–$800 per session | Bypasses the gut entirely | Raises levels; clinical benefit not established |
| Subcutaneous injection | $93–$186/mo | Good absorption, self-administered | Raises levels; clinical benefit not established |
| Nasal spray | $112–$135/mo | Mucosal absorption | Weakest supporting data of the routes |
| Oral NR or NMN | $40–$90/mo | Precursor the body converts | Reliably raises NAD in blood; outcomes unclear |
| Topical cream | $84–$90/mo | Local skin effect | Essentially a cosmetic claim |
Scroll the table sideways to see every column.
What the human research supports
NAD+ claims against the human evidence
The biochemistry is solid. The claims sold to consumers run considerably ahead of what has been shown in people.
Established biochemistry, not in dispute. NAD is required for the reactions that convert food into cellular energy, and it is found in every cell.
Reasonably well supported by measurement studies across tissues. Whether that decline causes age-related dysfunction, or simply accompanies it, is not resolved.
NR and NMN supplementation does reliably increase measurable NAD in blood in human studies. This is a biomarker result, not a health outcome.
Small and mixed human studies. Cleveland Clinic's assessment is that there is currently not enough research to confirm the energy benefits claimed for these products.
No human evidence of lifespan extension. The supporting work is in model organisms, where lifespan experiments are feasible and the results do not transfer straightforwardly to people.
Marketed by some clinics, supported mainly by case reports and uncontrolled series. Not established in controlled trials.
Ratings summarise the weight of published human evidence for the claim as marketed — not whether a substance is safe, and not a treatment recommendation. Tap a row for what the evidence consists of.
The GLP-1 connection, and why NAD+ appears at checkout
NAD+ shows up in GLP-1 price grids for the same reason sermorelin does: it is a high-margin cash product with no reference price. There is no branded NAD+ for a shopper to compare against, no insurance to adjudicate, and no approval process to constrain the claims.
There is a second, subtler reason. People starting a GLP-1 often report fatigue in the early weeks, partly because they are eating substantially less. "Low energy" is therefore a live complaint in exactly the population being offered an energy product — and one that resolves on its own for most people as intake stabilises.
If you are tired on a GLP-1, the first questions are whether you are eating enough protein, drinking enough fluid, and sleeping. Those explain far more early-treatment fatigue than cellular NAD decline does, and testing them costs nothing.
A reasonable position
NAD+ is not a scam in the way that some wellness products are — the underlying biology is real and actively researched, and the field may yet produce something useful. But being an interesting research area is not the same as being a product that works, and consumers are currently paying product prices for research-stage evidence.
If you want to try it anyway, the cheapest defensible version is an oral precursor, which has the best-characterised effect on measurable NAD levels and costs a fraction of injections or infusions. Spending $186 a month on injections, or several hundred per IV session, buys you a better absorption argument and no better evidence of benefit.